4//SEC Filing
Driscoll Martin J 4
Accession 0000905718-20-001131
CIK 0001566373other
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 11:14 AM ET
Size
19.2 KB
Accession
0000905718-20-001131
Insider Transaction Report
Form 4
Driscoll Martin J
DirectorPresident and CEO
Transactions
- Award
Common Stock
2020-11-19+15,000→ 47,600 total - Other
Warrants
2020-11-19−5,475→ 0 totalExercise: $43.16From: 2017-05-24Exp: 2021-11-23→ Common Stock (5,475 underlying) - Exercise/Conversion
Common Stock
2020-11-19+10,000→ 32,600 total - Sale
Common Stock
2020-11-20$4.76/sh−175$833→ 47,425 total - Exercise/Conversion
Restricted Stock Units
2020-11-19−10,000→ 0 total→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]Restricted stock units ("RSUs") converted into common stock on a one-for-one basis.
- [F2]All unvested issued and outstanding RSUs accelerated and vested in full in connection with the closing of the business combination with F-star Therapeutics Limited.
- [F3]The reported securities were called for redemption by the Issuer at their Black-Scholes value.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.64 to $4.88 per share. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Issuer
F-star Therapeutics, Inc.
CIK 0001566373
Entity typeother
Related Parties
1- filerCIK 0001339402
Filing Metadata
- Form type
- 4
- Filed
- Nov 22, 7:00 PM ET
- Accepted
- Nov 23, 11:14 AM ET
- Size
- 19.2 KB